Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuanghuang Gout Capsule is a Traditional Chinese Medicine (TCM) developed by Zhongshan Hengsheng Pharmaceutical for the treatment of gout and hyperuricemia. It is specifically formulated to address the "Qi deficiency, damp-heat, and blood stasis" syndrome (气虚湿热瘀阻证) in patients. The drug has been evaluated in Phase 2 clinical trials in China, where its efficacy and safety were compared against allopurinol tablets. As a botanical-based therapy, it is intended to lower serum uric acid levels and manage the inflammatory symptoms associated with gouty arthritis through multi-target mechanisms characteristic of its herbal constituents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuanghuang Gout Capsule.